4978.T

The company maintains a strong liquidity position, with a current ratio of 7.64, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 2,823,367,000 JPY, which supports its short-term obligations and operational flexibility. The price-to-book ratio of 1.49 suggests that the company's market value is slightly above its book value, reflecting investor confidence in its intangible assets and future earnings potential.

Profitability metrics reveal a mixed picture. The company reported a net income of 103,245,000 JPY, but its operating income was negative at -130,409,000 JPY, indicating operational challenges. The return on equity (ROE) of 1.15% and return on assets (ROA) of 1.07% are below the industry median for pharmaceutical firms, suggesting that the company is underperforming in terms of capital efficiency and asset utilization.

Geographically, the company's revenue is not disclosed by region, but its business is primarily concentrated in Japan. The lack of segmental or geographic breakdown limits the ability to assess diversification risk. The company's revenue concentration in a single market may expose it to regulatory, economic, and currency risks specific to Japan.

The company's growth trajectory appears to be constrained. With a negative operating income and a high price-to-earnings ratio of 129.78, the company is currently trading at a premium relative to its earnings. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability, and the company's capital expenditures are negative, suggesting a reduction in investment in long-term assets.

Risk factors include the company's negative operating income and the high P/E ratio, which may indicate overvaluation or underlying operational inefficiencies. The company has no long-term debt, which reduces financial leverage risk, but the absence of debt also suggests limited capital structure flexibility. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.

Recent events include the latest financial filing, which shows a net income of 103,245,000 JPY and a revenue of 2,978,627,000 JPY. The company's free cash flow of 67,261,000 JPY and operating cash flow of 6,287,000 JPY indicate that it is generating positive cash from operations, albeit at a modest level. The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets.